Sort by:

• Highly Influential Citations
• Citations
• Acceleration
• Velocity
• Recency

Learn More

A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic…

• Mark A. Tanner, Renzo Galanello, +8 authors D. J. Pennell
• Circulation
• 2007

BACKGROUND Cardiac complications secondary to iron overload are the leading cause of death in beta-thalassemia major. Approximately two thirds of patients maintained on the parenteral iron chelator… (More)

Myocardial iron loading in patients with thalassemia major on deferoxamine chelation.

• Mark A. Tanner, Renzo Galanello, +6 authors D. J. Pennell
• Journal of cardiovascular magnetic resonance…
• 2006

BACKGROUND Heart failure secondary to myocardial iron loading remains the leading cause of death in thalassemia major (TM). We used cardiovascular magnetic resonance (CMR) to assess the prevalence of… (More)

Combined chelation therapy in thalassemia major for the treatment of severe myocardial siderosis with left ventricular dysfunction

• Mark A. Tanner, Renzo Galanello, +7 authors D. Pennell
• Journal of cardiovascular magnetic resonance…
• 2008

BACKGROUND In thalassemia major (TM), severe cardiac siderosis can be treated by continuous parenteral deferoxamine, but poor compliance, complications and deaths occur. Combined chelation therapy… (More)

Effect of iron overload on the response to recombinant interferon-alfa treatment in transfusion-dependent patients with thalassemia major and chronic hepatitis C.

• Maria Grazia Clemente, Mauro Congia, +7 authors Carlo Dessì
• The Journal of pediatrics
• 1994

The purpose of this study was to determine whether interferon-alfa (IFN-alpha) therapy benefits patients with transfusion-dependent thalassemia and chronic active hepatitis C, and whether their iron… (More)

Relationship between transfusion regimen and suppression of erythropoiesis in beta-thalassaemia major.

• Marco Cazzola, Piero de Stefano, +6 authors Renzo Galanello
• British journal of haematology
• 1995

In the management of beta-thalassaemia major, different transfusion schemes are employed with baseline haemoglobin levels ranging from 8 to over 12 g/dl. We studied the relationship between… (More)

Genetic modifiers of β-thalassemia and clinical severity as assessed by age at first transfusion.

• Fabrice Danjou, Franco Anni, +6 authors Renzo Galanello
• Haematologica
• 2012

BACKGROUND The clinical and hematologic features of β-thalassemia are modulated by different factors, resulting in a wide range of clinical severity. The main factors are the type of disease-causing… (More)

Depletion of trace elements and acute ocular toxicity induced by desferrioxamine in patients with thalassaemia.

• Stefano De Virgiliis, Mauro Congia, +6 authors A. Cao
• Archives of disease in childhood
• 1988

High doses of intravenous desferrioxamine infused over a short period of time induce a large faecal and urinary iron excretion but also produce retinal abnormalities that are characterised by… (More)

Serum ferritin, desferrioxamine, and evolution of HIV-1 infection in thalassemic patients.

• Yahia Salhi, Dominique Costagliola, +5 authors Robert Girot
• Journal of acquired immune deficiency syndromes…
• 1998

To study the respective roles of mean serum ferritin level and the mean desferrioxamine (DFX) dose on progression of HIV-1 infection, data from 49 HIV-seropositive thalassemic patients were analyzed… (More)

Toward optimizing the use of deferasirox: potential benefits of combined use with deferoxamine.

• Robert W. Grady, Renzo Galanello, Rachel E Randolph, Dorothy A. Kleinert, Carlo Dessì, Patricia J V Giardina
• Haematologica
• 2013

Patients with β-thalassemia require iron chelation therapy to protect against progressive iron overload and non-transferrin-bound iron. Some patients fail to respond adequately to deferoxamine and… (More)

Long-term health-related quality of life evaluated more than 20 years after hematopoietic stem cell transplantation for thalassemia.

• Giorgio La Nasa, Giovanni Caocci, +8 authors Guido Lucarelli
• Blood
• 2013

The principal aim of our study was to investigate whether patients transplanted more than 20 years ago for β-thalassemia major had a different health-related quality of life (HRQoL) compared with the… (More)

• ‹
• 1
• 2
• 3
• 4
• ›